Fixed Dose Combination Products [Design Issues]

posted by joyjac – Philippines, 2007-03-23 09:47 (7034 d 13:58 ago) – Posting: # 597
Views: 4,740

Dear colleagues,

Is it possible to apply scaled ABE on one active drug ingredient identified as a highly variable drug/drug product based on a previous study and on published literature, but make use of the conventional ABE approach for the other active drug component identified as not highly variable? Of course this will be stated a priori in the protocol. Your insight on this would be appreciated. Thanks.

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,571 registered users;
127 visitors (0 registered, 127 guests [including 29 identified bots]).
Forum time: 00:45 CEST (Europe/Vienna)

The great tragedy of Science – the slaying
of a beautiful hypothesis by an ugly fact.    Thomas Henry Huxley

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5